Zentrum für klinische Studien Alexander Segner

The site focuses on atherosclerotic cardiovascular disease and related conditions such as elevated lipoprotein(a). Studies aim to test new lipid‑lowering agents, assess their impact on major adverse cardiovascular events, and improve overall heart health.

• Evaluation of inclisiran for LDL‑cholesterol reduction
• Assessment of pelacarsen in lowering lipoprotein(a) levels
• Investigation of lepodisiran on cardiovascular event risk
• Retatrutide trials targeting heart‑related outcomes and kidney function
• Tirzepatide studies comparing cardiovascular event rates
• AZD0780 research on serious heart, stroke, or vascular complications

Zentrum für klinische Studien Alexander Segner conducts these trials to advance therapies that can lower cholesterol, reduce plaque buildup, and prevent heart attacks and strokes.

Research at the center addresses obesity, overweight, and diabetes, including both type 1 and type 2 diabetes. The primary goal is to evaluate novel weight‑loss medicines, improve glycaemic control, and study long‑term safety for conditions such as diabetic retinopathy.

• AZD5004 trials for weight loss in adults with obesity or overweight
• Maridebart cafraglutide studies on body‑weight reduction and cardiovascular outcomes
• Orforglipron versus dapagliflozin for glycaemic management
• Semaglutide safety study on diabetic eye disease progression
• Insulin icodec combined with insulin aspart for type 1 diabetes control
• CagriSema investigations for weight loss in patients with type 2 diabetes
• NNC0487-0111 CCI evaluation for sustained weight‑loss maintenance

Located in St. Ingbert, Germany, the Zentrum für klinische Studien Alexander Segner is dedicated to finding effective treatments that help patients manage weight, control blood sugar, and prevent diabetes‑related complications.